Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 63

Sort by

Sort Order Select

Journal Articles

Diagnosis and Disease Burden of Von Willebrand Disease in a Large US Population Based-Dataset

Michelle Sholzberg, Angela C Weyand, Jacob S Lai, Benjamin Kim, Gary Patou, Nicole M. Engel-Nitz, Qiana Amos, Robert F. Sidonio, Jr.

Blood (2024) 144 (Supplement 1): 3980.

https://doi.org/10.1182/blood-2024-206631

Published: 2024

Journal Articles

Disparities in Real-World Treatment Patterns Among Patients with Von Willebrand Disease in a Large US Population-Based Dataset

Angela C Weyand, Michelle Sholzberg, Jacob S Lai, Benjamin Kim, Adam Rosenthal, Scott M Robertson, Gary Patou, Robert F. Sidonio, Jr.

Blood (2024) 144 (Supplement 1): 3978.

https://doi.org/10.1182/blood-2024-206567

Published: 2024

Journal Articles

Efficacy and Safety of Prophylaxis with a Plasma-Derived Von Willebrand Factor/Factor VIII Concentrate Among Von Willebrand Disease Patients across All ABO Antigen Blood Groups

Robert F. Sidonio, Jr.

Blood (2024) 144 (Supplement 1): 3985.

https://doi.org/10.1182/blood-2024-194448

Published: 2024

Journal Articles

Increased Prophylactic Dosing Frequency Effectively Improve Bleeding Rates in Von Willebrand Disease Patients Who Require Higher Hemostatic Coverage - a Sub-Analysis of Data from the Wil-31 Study

Robert F Sidonio, Jr.

Blood (2024) 144 (Supplement 1): 5498.

https://doi.org/10.1182/blood-2024-193886

Published: 2024

Journal Articles

Continuous Prophylaxis with Recombinant Von Willebrand Factor in People with Clinically Severe Congenital Types 1 and 2 Von Willebrand Disease in a Real-World Setting: Interim Analysis of Athn 9, a Natural History Study for People with Severe VWD

Robert F Sidonio, Jr., Angela C Weyand, Tammuella Chrisentery-Singleton, Martin Chandler, Carol Fedor, Priscilla Driscoll-Shempp, Michelle Kirby, Jorge Caicedo

Blood (2024) 144 (Supplement 1): 2594.

https://doi.org/10.1182/blood-2024-200261

Published: 2024

Journal Articles

Strategies for Immune Tolerance Induction in Hemophilia a Patients with Inhibitors: The First Prespecified Interim Analysis from the Motivate Study

Carmen Escuriola, Robert F. Sidonio, Jr.

Blood (2024) 144 (Supplement 1): 5475.

https://doi.org/10.1182/blood-2024-193874

Published: 2024

Journal Articles

Development of a Working Definition of Severe Von Willebrand Disease

Tung Wynn, Christopher Walsh, Jeanette Cesta, Robert F Sidonio, Jr., Stefanie Dugan, Mona Sayedul Huq

Blood (2024) 144 (Supplement 1): 5019.

https://doi.org/10.1182/blood-2024-208188

Published: 2024

Journal Articles

Immune Toleration Induction with Emicizumab in Hemophilia a Patients with Inhibitors: A Systematic Review

Prashant Raghavendran, Robert F Sidonio, Jr., Glaivy Batsuli

Blood (2024) 144 (Supplement 1): 1206.

https://doi.org/10.1182/blood-2024-207335

Published: 2024

Journal Articles

RNAing toward a new therapy for hemophilia

Bhavya S. Doshi, Robert F. Sidonio, Jr

Blood (2024) 143 (22): 2219–2221.

https://doi.org/10.1182/blood.2024024295

Published: 2024

Journal Articles

Immunogenicity of a Plasma-Derived Von Willebrand Factor/Factor VIII Concentrate during the Wil-31 Prophylaxis Study in Patients with Von Willebrand Disease

Claudia Djambas Khayat, Robert F Sidonio, Jr., Anna Pavlova

Blood (2023) 142 (Supplement 1): 5485.

https://doi.org/10.1182/blood-2023-180585

Published: 2023

Journal Articles

Effect of Factor VIII and Von Willebrand Factor Activities on Number of Bleeding Events in Previously Treated Patients with Von Willebrand Disease on Regular Prophylaxis with a Plasma-Derived Von Willebrand Factor/Factor VIII Concentrate

Kateryna V Vilchevska, Vladimir Vdovin, Margarita Timofeeva, Claudia Djambas Khayat, Adlette Inati, Robert F Sidonio, Jr.

Blood (2023) 142 (Supplement 1): 5510.

https://doi.org/10.1182/blood-2023-180526

Published: 2023

Journal Articles

Design of an Observational Study (PROVE) to Assess the Long-Term Effects of Prophylaxis with Simoctocog Alfa or Emicizumab on Joint and Bone Health in Hemophilia a Patients

Robert Klamroth, Robert F Sidonio, Jr., Yesim Dargaud, Víctor Jiménez-Yuste, Rolf Ljung, Guy Young, Pratima Chowdary

Blood (2023) 142 (Supplement 1): 1255.

https://doi.org/10.1182/blood-2023-181725

Published: 2023

Journal Articles

Efficacy and Safety of Prophylaxis with a Plasma-Derived Von Willebrand Factor/Factor VIII Concentrate in Children and Adolescents with Von Willebrand Disease - a Sub-Analysis of Data from the Wil-31 Study

Robert F Sidonio, Jr., Leonid Dubey, Kateryna V Vilchevska, Adlette Inati, Claudia Djambas Khayat

Blood (2023) 142 (Supplement 1): 3992.

https://doi.org/10.1182/blood-2023-180513

Published: 2023

Journal Articles

Efficacy of Regular Prophylaxis with a Plasma-Derived Von Willebrand Factor/Factor VIII Concentrate in Reducing Heavy Menstrual Bleeding in Females with Von Willebrand Disease

Csongor Kiss, Zoltan Boda, Claudia Djambas Khayat, Leonid Dubey, Robert F Sidonio, Jr.

Blood (2023) 142 (Supplement 1): 3997.

https://doi.org/10.1182/blood-2023-180498

Published: 2023

Journal Articles

Efficacy of Regular Prophylaxis with a Plasma-Derived Von Willebrand Factor/Factor VIII Concentrate in Reducing Nose Bleeds in Children and Adults with Von Willebrand Disease

Ana Boban, Robert F Sidonio, Jr., Leonid Dubey, Kateryna V Vilchevska, Adlette Inati, Claudia Djambas Khayat

Blood (2023) 142 (Supplement 1): 5509.

https://doi.org/10.1182/blood-2023-180029

Published: 2023

Journal Articles

Reproductive Health Needs in Patients with Bleeding Disorders

Divyaswathi Citla Sridhar, Robert F. Sidonio, Jr., Sanjay Ahuja

Blood (2022) 140 (Supplement 1): 7985–7986.

https://doi.org/10.1182/blood-2022-170085

Published: 2022

Journal Articles

Quality of Life in Patients with Clinically Severe Von Willebrand Disease: Interim Analysis of Athn 9: A Natural History Study for People with Severe Von Willebrand Disease (VWD)

Angela C. Weyand, Martin Chandler, Carol Fedor, Michael Recht, Robert F. Sidonio, Jr.

Blood (2022) 140 (Supplement 1): 5600–5602.

https://doi.org/10.1182/blood-2022-163302

Published: 2022

Journal Articles

Eptacog Beta Efficacy in Treating Mild or Moderate Bleeds in Target Joints of Individuals with Hemophilia A or B and Inhibitors in PERSEPT 1

Blood (2022) 140 (Supplement 1): 5597–5599.

https://doi.org/10.1182/blood-2022-156110

Published: 2022

Journal Articles

Clinical Characteristics Impacting Health-Related Quality of Life in Persons with Von Willebrand Disease

Shannon L Carpenter, Joanne Wu, Jonathan C. Roberts, Roshni Kulkarni, Peter A. Kouides, Robert F. Sidonio, Jr., Barbara Konkle, Judith Baker, Megan M. Ullman, Randall Curtis, Nicole Crook, Michael B. Nichol

Blood (2022) 140 (Supplement 1): 5127–5128.

https://doi.org/10.1182/blood-2022-160463

Published: 2022

Journal Articles

Efficacy and Safety of Prophylaxis with a Plasma-Derived Von Willebrand Factor/ Factor VIII Concentrate in Previously Treated Patients with Von Willebrand Disease

Robert F. Sidonio, Jr., Ana Boban, Leonid Dubey, Adlette Inati, Csongor Kiss, Toshko Lissitchkov, Dzmitry Novik, Elina Peteva, Ali T. Taher, Margarita Arkadevna Timofeeva, Kateryna V. Vilchevska, Vladimir Vdovin, Sylvia Werner, Sigurd Knaub, Claudia Khayat

Blood (2022) 140 (Supplement 1): 8438–8439.

https://doi.org/10.1182/blood-2022-162358

Published: 2022

NARROW

Diagnosis and Disease Burden of Von Willebrand Disease in a Large US Population Based-Dataset

Disparities in Real-World Treatment Patterns Among Patients with Von Willebrand Disease in a Large US Population-Based Dataset

Efficacy and Safety of Prophylaxis with a Plasma-Derived Von Willebrand Factor/Factor VIII Concentrate Among Von Willebrand Disease Patients across All ABO Antigen Blood Groups

Increased Prophylactic Dosing Frequency Effectively Improve Bleeding Rates in Von Willebrand Disease Patients Who Require Higher Hemostatic Coverage - a Sub-Analysis of Data from the Wil-31 Study

Continuous Prophylaxis with Recombinant Von Willebrand Factor in People with Clinically Severe Congenital Types 1 and 2 Von Willebrand Disease in a Real-World Setting: Interim Analysis of Athn 9, a Natural History Study for People with Severe VWD

Strategies for Immune Tolerance Induction in Hemophilia a Patients with Inhibitors: The First Prespecified Interim Analysis from the Motivate Study

Development of a Working Definition of Severe Von Willebrand Disease

Immune Toleration Induction with Emicizumab in Hemophilia a Patients with Inhibitors: A Systematic Review

RNAing toward a new therapy for hemophilia

Immunogenicity of a Plasma-Derived Von Willebrand Factor/Factor VIII Concentrate during the Wil-31 Prophylaxis Study in Patients with Von Willebrand Disease

Effect of Factor VIII and Von Willebrand Factor Activities on Number of Bleeding Events in Previously Treated Patients with Von Willebrand Disease on Regular Prophylaxis with a Plasma-Derived Von Willebrand Factor/Factor VIII Concentrate

Design of an Observational Study (PROVE) to Assess the Long-Term Effects of Prophylaxis with Simoctocog Alfa or Emicizumab on Joint and Bone Health in Hemophilia a Patients

Efficacy and Safety of Prophylaxis with a Plasma-Derived Von Willebrand Factor/Factor VIII Concentrate in Children and Adolescents with Von Willebrand Disease - a Sub-Analysis of Data from the Wil-31 Study

Efficacy of Regular Prophylaxis with a Plasma-Derived Von Willebrand Factor/Factor VIII Concentrate in Reducing Heavy Menstrual Bleeding in Females with Von Willebrand Disease

Efficacy of Regular Prophylaxis with a Plasma-Derived Von Willebrand Factor/Factor VIII Concentrate in Reducing Nose Bleeds in Children and Adults with Von Willebrand Disease

Reproductive Health Needs in Patients with Bleeding Disorders

Quality of Life in Patients with Clinically Severe Von Willebrand Disease: Interim Analysis of Athn 9: A Natural History Study for People with Severe Von Willebrand Disease (VWD)

Eptacog Beta Efficacy in Treating Mild or Moderate Bleeds in Target Joints of Individuals with Hemophilia A or B and Inhibitors in PERSEPT 1

Clinical Characteristics Impacting Health-Related Quality of Life in Persons with Von Willebrand Disease

Efficacy and Safety of Prophylaxis with a Plasma-Derived Von Willebrand Factor/ Factor VIII Concentrate in Previously Treated Patients with Von Willebrand Disease

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only